Last reviewed · How we verify
99m-TC-PSMA-I&S
99m-TC-PSMA-I&S is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging of prostate cancer.
99m-TC-PSMA-I&S is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging of prostate cancer. Used for Diagnostic imaging of prostate cancer.
At a glance
| Generic name | 99m-TC-PSMA-I&S |
|---|---|
| Sponsor | IRCCS San Raffaele |
| Drug class | Radiopharmaceutical |
| Target | PSMA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to PSMA, a protein overexpressed on the surface of prostate cancer cells, allowing for visualization of tumors through positron emission tomography (PET) imaging. This enables accurate diagnosis and staging of prostate cancer, as well as assessment of treatment response.
Approved indications
- Diagnostic imaging of prostate cancer
Common side effects
- None reported
Key clinical trials
- Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 99m-TC-PSMA-I&S CI brief — competitive landscape report
- 99m-TC-PSMA-I&S updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI